Systems Biology of Vaccination for Seasonal Influenza in Humans

Overview

Journal Nat Immunol

Date 2011 Jul 12

PMID 21743478

Citations 524

Authors

Helder I Nakaya

Jens Wrammert

Eva K Lee

Luigi Racioppi

Stephanie Marie-Kunze

W Nicholas Haining

Anthony R Means

Sudhir P Kasturi

Nooruddin Khan

Gui-Mei Li

Megan McCausland

Vibhu Kanchan

Kenneth E Kokko

Shuzhao Li

Rivka Elbein

Aneesh K Mehta

Alan Aderem

Kanta Subbarao

Rafi Ahmed

Bali Pulendran

Affiliations

Soon will be listed here.

Abstract

Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.

Citing Articles

Integrative Mapping of Pre-existing Immune Landscapes for Vaccine Response Prediction.

Hao S, Tomic I, Lindsey B, Jagne Y, Hoschler K, Meijer A bioRxiv. 2025; .

PMID: 39896552 PMC: 11785181. DOI: 10.1101/2025.01.22.634302.

Predictive signatures of immune response to vaccination and implications of the immune setpoint remodeling.

Ramos I mSphere. 2025; 10(2):e0050224.

PMID: 39853092 PMC: 11852852. DOI: 10.1128/msphere.00502-24.

System vaccinology analysis of predictors and mechanisms of antibody response durability to multiple vaccines in humans.

Cortese M, Hagan T, Rouphael N, Wu S, Xie X, Kazmin D Nat Immunol. 2025; 26(1):116-130.

PMID: 39747435 DOI: 10.1038/s41590-024-02036-z.

The alteration of cortical microstructure similarity in drug-resistant epilepsy correlated with mTOR pathway genes.

Cao H, Wei P, Huang Y, Wang N, Guo L, Fan X EBioMedicine. 2024; 97:104847.

PMID: 39492369 PMC: 10628344. DOI: 10.1016/j.ebiom.2023.104847.

Targeting immunosenescence for improved tumor immunotherapy.

Liu Z, Zuo L, Zhou Z, Liu S, Ba Y, Zuo A MedComm (2020). 2024; 5(11):e777.

PMID: 39473905 PMC: 11518697. DOI: 10.1002/mco2.777.

References

Gaucher D, Therrien R, Kettaf N, Angermann B, Boucher G, Filali-Mouhim A . Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med. 2008; 205(13):3119-31. PMC: 2605227. DOI: 10.1084/jem.20082292. View

Sullivan S, Jacobson R, Poland G . Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine. Expert Rev Vaccines. 2010; 9(10):1127-33. DOI: 10.1586/erv.10.117. View

Talbot H, Rock M, Johnson C, Tussey L, Kavita U, Shanker A . Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLoS One. 2011; 5(12):e14442. PMC: 3010987. DOI: 10.1371/journal.pone.0014442. View

Moldoveanu Z, Clements M, Prince S, Murphy B, Mestecky J . Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine. 1995; 13(11):1006-12. DOI: 10.1016/0264-410x(95)00016-t. View

Fiore A, Uyeki T, Broder K, Finelli L, Euler G, Singleton J . Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010; 59(RR-8):1-62. View

Belshe R . Current status of live attenuated influenza virus vaccine in the US. Virus Res. 2004; 103(1-2):177-85. DOI: 10.1016/j.virusres.2004.02.031. View

Thomas R, Matthias T, Witte T . Leukocyte immunoglobulin-like receptors as new players in autoimmunity. Clin Rev Allergy Immunol. 2009; 38(2-3):159-62. DOI: 10.1007/s12016-009-8148-8. View

Ron D, Walter P . Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007; 8(7):519-29. DOI: 10.1038/nrm2199. View

He X, Holmes T, Zhang C, Mahmood K, Kemble G, Lewis D . Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol. 2006; 80(23):11756-66. PMC: 1642596. DOI: 10.1128/JVI.01460-06. View

10.

Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R . Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol. 2003; 171(10):4969-73. DOI: 10.4049/jimmunol.171.10.4969. View

11.

Hirota Y, Kaji M, Ide S, Kajiwara J, Kataoka K, Goto S . Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. Vaccine. 1997; 15(9):962-7. DOI: 10.1016/s0264-410x(96)00302-7. View

12.

Wang S, Ribar T, Means A . Expression of Ca(2+)/calmodulin-dependent protein kinase IV (caMKIV) messenger RNA during murine embryogenesis. Cell Growth Differ. 2001; 12(7):351-61. View

13.

Iwakoshi N, Lee A, Vallabhajosyula P, Otipoby K, Rajewsky K, Glimcher L . Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol. 2003; 4(4):321-9. DOI: 10.1038/ni907. View

14.

Pulendran B, Li S, Nakaya H . Systems vaccinology. Immunity. 2010; 33(4):516-29. PMC: 3001343. DOI: 10.1016/j.immuni.2010.10.006. View

15.

Anderson K, Means A . Defective signaling in a subpopulation of CD4(+) T cells in the absence of Ca(2+)/calmodulin-dependent protein kinase IV. Mol Cell Biol. 2001; 22(1):23-9. PMC: 134209. DOI: 10.1128/MCB.22.1.23-29.2002. View

16.

Huleatt J, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A . Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine. 2007; 26(2):201-14. DOI: 10.1016/j.vaccine.2007.10.062. View

17.

Wrammert J, Smith K, Miller J, Langley W, Kokko K, Larsen C . Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 2008; 453(7195):667-71. PMC: 2515609. DOI: 10.1038/nature06890. View

18.

Treanor J, Taylor D, Tussey L, Hay C, Nolan C, Fitzgerald T . Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine. 2010; 28(52):8268-74. DOI: 10.1016/j.vaccine.2010.10.009. View

19.

Barrett A, Teuwen D . Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?. Curr Opin Immunol. 2009; 21(3):308-13. DOI: 10.1016/j.coi.2009.05.018. View

20.

Querec T, Akondy R, Lee E, Cao W, Nakaya H, Teuwen D . Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. 2008; 10(1):116-125. PMC: 4049462. DOI: 10.1038/ni.1688. View